PreveCeutical - Appoints Dr. Maher Khaled as Director of International Operations
Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces the appointment of Dr. Maher Khaled as the Company’s Director of International Operations.
Dr. Khaled brings a broad range of expertise and experience to PreveCeutical. He has commercialised therapeutic and diagnostic technologies for over a decade, most recently at UniQuest Pty Ltd (“UniQuest”), where he managed intellectual property arising from medical research at the University of Queensland, Australia. He was also at the University of Cambridge, United Kingdom for over six years, where he was an Investment Manager with Cambridge Enterprise Seed Funds. He has held directorships with various companies, including start-up companies that he assisted with raising capital. Dr. Khaled has also worked at McKinsey & Co.’s London, England office, where he provided advice on strategic and operational issues to clients in the pharmaceutical, healthcare and medical device industries. He holds a PhD in Biotechnology, a BSc in Biomedical Science and a Bachelor of Laws (LLB) from the University of Queensland.
Dr. Khaled will be involved in overseeing PreveCeutical’s development of therapeutic technologies, as well as managing the Company’s operations in Australia. He will also be reviewing acquisition and licensing opportunities, leading PreveCeutical’s commercialisation efforts for its growing portfolio of intellectual property, and engaging with industry professionals to track existing and emerging trends and foster strategic relationships. In this role, Dr. Khaled will be working closely with Dr. Harry Parekh, PreveCeutical’s Chief Research Officer.
“We are delighted to have Dr. Khaled as part of our team,” said Stephen Van Deventer, Chairman and CEO of the Company. “Dr. Khaled’s degrees in law and science, as well as his experience in commercialising therapeutic and diagnostic technologies will be of tremendous benefit to PreveCeutical and its shareholders.”
Dr. Khaled commented, “I am excited by the partnership opportunities offered by the commercial ventures PreveCeutical both has, and is planning. I look forward to pursuing these partnerships internationally whilst working closely with Dr. Parekh to advance the therapeutic research programs he is leading at the University of Queensland.”
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the Company’s website.
For more information about PreveCeutical, please visit
www.PreveCeutical.com, follow us on Twitter:
http://twitter.com/PreveCeuticals and Facebook:
On Behalf of the Board of Directors
“Stephen Van Deventer”
Chairman & CEO
For further information, please contact:
Director of Corporate Communications & Investor Relations
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future including the Company's anticipated business plans, and the prospect of its ability and success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “pro forma”, “plans”, “expects”, “may”, “should”, “budget”, “schedules”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialise therapeutic and diagnostic technologies, pursue business partnerships, complete its research programs as planned, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.